Results 171 to 180 of about 18,010 (199)
Some of the next articles are maybe not open access.
Oxygenator impact on meropenem/vaborbactam in extracorporeal membrane oxygenation circuits
Perfusion, 2021Introduction: To determine the oxygenator impact on alterations of meropenem (MEM)/vaborbactam (VBR) in a contemporary neonatal/pediatric (1/4-inch) and adolescent/adult (3/8-inch) extra corporeal membrane oxygenation (ECMO) circuit including the Quadrox-i ®
Jeffrey J Cies +8 more
openaire +2 more sources
Antimicrobial Agents and Chemotherapy, 2018 Meropenem-vaborbactam is a fixed combination of the novel β-lactamase inhibitor vaborbactam and the carbapenem antibiotic meropenem, developed for the treatment of serious infections caused by drug-resistant Gram-negative bacteria.
Michael N Dudley
exaly +2 more sources
An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia
Expert Opinion on Pharmacotherapy, 2020Introduction: Nosocomial pneumonias are the second most common healthcare-associated infections (HCAIs), often associated with the presence of Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter species, and Enterobacter species.
Lauren M. Groft +2 more
openaire +2 more sources
A Brief Review of a New Antibiotic: Meropenem-vaborbactam
The Senior Care Pharmacist, 2019Meropenem-vaborbactam is a newly approved antibiotic for complex urinary tract infections and to treat carbapenem-resistant Enterobacteriaceae infections. Its advantage over meropenem is the betalactamase inhibitor which slows bacterial resistance. This medication has been studied in numerous countries and has relatively few side effects.
openaire +2 more sources
Drugs of Today, 2017
On August 29, 2017, the United States Food and Drug Administration (FDA) approved meropenem/ vaborbactam fixed combination for the treatment of adults with complicated urinary tract infections (cUTI). The decision was based on substantial preclinical and clinical data, including two recent trials involving hundreds of adults with cUTI.
M W, McCarthy, T J, Walsh
openaire +2 more sources
On August 29, 2017, the United States Food and Drug Administration (FDA) approved meropenem/ vaborbactam fixed combination for the treatment of adults with complicated urinary tract infections (cUTI). The decision was based on substantial preclinical and clinical data, including two recent trials involving hundreds of adults with cUTI.
M W, McCarthy, T J, Walsh
openaire +2 more sources
Expert Opinion on Pharmacotherapy, 2018
Meropenem-vaborbactam is a new beta-lactam/beta-lactamase inhibitor combination that combines a carbapenem antibiotic with a first-in-class, boronic acid pharmacophore, serine beta-lactamase inhibitor which has potent inhibitory activity against class A carbapenemases, especially Klebsiella pneumoniae carbapenemases (KPC), in addition to other class A ...
Gary, Wu, Eunah, Cheon
openaire +2 more sources
Meropenem-vaborbactam is a new beta-lactam/beta-lactamase inhibitor combination that combines a carbapenem antibiotic with a first-in-class, boronic acid pharmacophore, serine beta-lactamase inhibitor which has potent inhibitory activity against class A carbapenemases, especially Klebsiella pneumoniae carbapenemases (KPC), in addition to other class A ...
Gary, Wu, Eunah, Cheon
openaire +2 more sources